Begin main content

Combination Inhaled Corticosteroids and Long-Acting Beta2-Agonists for Acute Respiratory Tract Infections and Cough: Clinical Effectiveness

Published on: June 15, 2016
Project Number: RB0996-000
Product Line: Rapid Response
Research Type: Drug
Report Type: Summary of Abstracts
Result type: Report

Question

  1. What is the clinical effectiveness of combination inhaled corticosteroids and long-acting beta2-agonists for patients with acute bacterial upper respiratory tract infections?
  2. What is the clinical effectiveness of combination inhaled corticosteroids and long-acting beta2-agonists for patients with acute viral upper respiratory tract infection?
  3. What is the clinical effectiveness of combination inhaled corticosteroids and long-acting beta2-agonists for patients with post-infectious or subacute cough?
  4. What is the clinical effectiveness of combination inhaled corticosteroids and long-acting beta2-agonists for patients with chronic cough?
  5. What is the clinical effectiveness of combination inhaled corticosteroids and long-acting beta2-agonists for patients with cough in sarcoidosis?

Key Message

No relevant literature was identified regarding the clinical effectiveness of combination inhaled corticosteroids and long-acting beta2-agonists for patients with respiratory tract infections, post-infectious or subacute cough, chronic cough, or cough in sarcoidosis.

Tags

administration, adrenergic beta-agonists, budesonide, cough, glucocorticoids, inhalation, respiration disorders, sarcoidosis, respiratory, Adrenergic, Advair, Breo Ellipta, ICS, LABA, Receptors, Symbicort, URTI, Zenhale, beta-2, fluticasone, formoterol, mometasone, salmeterol, vilanterol